Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RARE | CLUSTER | neutral | 2/10 | Two Ultragenyx insiders (CFO and Chief Medical Officer) sold a combined $125K in open-market transactions over the past | May 6, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK held its 26th Annual General Meeting on May 6, 2026, with all 25 resolutions passed by a majority. The filing is a r | May 6, 2026 |
| RGPX | 8-K | bearish | 6/10 | Regenerex Pharma terminated its CFO Kenneth Perry for cause following a committee review of audit-related findings. An i | May 6, 2026 |
| CLRB | 424B5 | bearish | 7/10 | Cellectar Biosciences is conducting a dilutive public offering of 1.6M shares at $2.65 (6.4% discount to last close) alo | May 6, 2026 |
| LNZA | PRESS-RELEASE | neutral | 3/10 | LanzaTech entered a multi-year R&D partnership with BRIGHT (DTU) to develop a C1 biofoundry for converting carbon emissi | May 6, 2026 |
| ACTU | DEFA14A | neutral | 4/10 | Actuate Therapeutics filed a proxy supplement disclosing the appointment of Dr. Martin H. Huber as an independent direct | May 6, 2026 |
| ACTU | 8-K | neutral | 4/10 | Actuate Therapeutics appointed Martin H. Huber, MD, as an independent director, expanding the board from 7 to 8 members. | May 6, 2026 |
| EVOTF | 6-K | bearish | 6/10 | Evotec SE reported Q1 2026 results with a 22% revenue decline to €156.6M and Adjusted EBITDA swinging to -€21.9M from +€ | May 6, 2026 |
| PLSE | 8-K | neutral | 3/10 | Pulse Biosciences disclosed that its Board authorized TD Cowen to sell common stock to company affiliates under an exist | May 6, 2026 |
| ERNA | PRESS-RELEASE | neutral | 5/10 | Ernexa Therapeutics announced preclinical data showing its lead cell therapy candidate ERNA-101, combined with PD-1 bloc | May 6, 2026 |
| IFRX | 6-K | bullish | 7/10 | InflaRx announced it will develop izicopan, an oral C5aR inhibitor, in ANCA-associated vasculitis (AAV) and additional r | May 6, 2026 |
| CDT | PRESS-RELEASE | neutral | 4/10 | CDT Equity announced that AZD5904, a myeloperoxidase inhibitor licensed from AstraZeneca, has entered the PCT phase for | May 6, 2026 |
| IFRX | PRESS-RELEASE | neutral | 5/10 | InflaRx announced a strategic pivot to develop izicopan in ANCA-associated vasculitis (AAV) and other renal diseases, wi | May 6, 2026 |
| TSHA | 8-K | neutral | 5/10 | Taysha Gene Therapies reported Q1 2026 financial results with a net loss of $42.4M ($0.12/share), wider than the $21.5M | May 6, 2026 |
| IFRX | 6-K | neutral | 4/10 | InflaRx reported Q1 2026 results: no revenue (GOHIBIC sales discontinued Dec 2025), net loss of €5.6M (improved from €8. | May 6, 2026 |
| ALLR | 8-K | neutral | 3/10 | Allarity Therapeutics announced that its Phase 3 API manufacturing campaign for stenoparib is on track for completion by | May 6, 2026 |
| URGN | PRESS-RELEASE | bullish | 7/10 | UroGen reported Q1 2026 total revenue of $51.0M (+152% YoY), driven by ZUSDURI's launch ($29.2M, +109% QoQ) and JELMYTO | May 6, 2026 |
| JAGX | DEFA14A | neutral | 1/10 | Jaguar Health filed a DEFA14A supplement to correct a typographical error in its April 30, 2026 proxy statement, the mee | May 6, 2026 |
| TSHA | PRESS-RELEASE | mixed | 7/10 | Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08 consensus, with zero revenue vs $2.3M a year ago. Th | May 6, 2026 |
| NVAX | 8-K | neutral | 4/10 | Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in non-cash APA close-out | May 6, 2026 |
| GLMD | 6-K | neutral | 3/10 | Galmed Pharmaceuticals announced a collaboration with Tissue Dynamics to develop a human cardiac fibrosis organoid platf | May 6, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 5/10 | BriaCell received FDA clearance to begin a Phase 1/2a clinical trial for Bria-BRES+, its next-generation personalized im | May 6, 2026 |
| RPRX | 8-K | bullish | 6/10 | Royalty Pharma reported Q1 2026 Portfolio Receipts of $925M (+10% YoY) and Royalty Receipts of $887M (+13% YoY), driven | May 6, 2026 |
| ALT | PRESS-RELEASE | neutral | 1/10 | Altimmune, Inc announced it will report its Q1 2026 results on May 13, 2026. | May 6, 2026 |
| MDCX | PRESS-RELEASE | bullish | 7/10 | Medicus Pharma announced positive dose-response results from an expanded analysis of its Phase 2 SKNJCT-003 study for Do | May 6, 2026 |
| BBIO | PRESS-RELEASE | bullish | 7/10 | BridgeBio Pharma announced that Brazilian health regulator ANVISA approved acoramidis (BEYONTTRA) for ATTR-CM, adding a | May 6, 2026 |
| TGTX | 8-K | bullish | 7/10 | TG Therapeutics reported Q1 2026 revenue of $204.9M, well above the $201.2M consensus, and raised full-year 2026 BRIUMVI | May 6, 2026 |
| LFCR | 8-K | bearish | 7/10 | Lifecore Biomedical reported Q1 2026 revenue of $23.2M, a 34% decline YoY from $35.2M, and a net loss of $15.0M ($0.43/s | May 6, 2026 |
| XFOR | PRESS-RELEASE | mixed | 6/10 | X4 Pharmaceuticals reported Q1 2026 revenue of $2.7M (vs $3.2M consensus) and GAAP EPS of -$0.16 (vs consensus -$0.20, a | May 6, 2026 |
| TCRX | 8-K | neutral | 4/10 | TScan Therapeutics reported Q1 2026 revenue of $1.0M (down 55% YoY from $2.2M) and a net loss of $28.7M ($-0.22 EPS), sl | May 6, 2026 |